Skip to content Skip to footer
Subscribe Now
NEWS

Jazz Pharmaceuticals Enters a ~$1.03B Licensing Deal with Saniona for SAN2355

Shots: Jazz Pharmaceuticals has entered into a global license agreement with Saniona to develop SAN2355 for epilepsy & other potential indications As per the deal, Jazz will lead & fund development, regulatory filings, & global commercialization in exchange for $42.5M upfront, ~$192.5M in development & regulatory milestones (incl. $7.5M at P-I initiation), ~$800M in commercial milestones, &…
4 days ago

Read more

Pierre Fabre & RedRidge Bio
NEWS

Pierre Fabre Laboratories and RedRidge Bio Enter R&D Collaboration & License Agreement for Biparatopic Antibody (BPA) Candidates

Shots: Pierre Fabre has partnered with RedRidge for BPA drugs against various targets in oncology, dermatology & rare diseases, where the latter will engineer, screen, & characterize BPAs for jointly selected targets, while Pierre will advance 2 co-development programs As per the deal, RedRidge will hold marketing rights in the US, Canada, & Japan…
March 12, 2025

Read more

VIEWPOINTS_Craig Thompson_2023
VIEWPOINTS

Craig Thompson, CEO of Cerevance Shares Insights from the Preclinical Data Presented at the Society for Neuroscience (SFN) 2022

Shots:   Craig shared with our readers the preclinical study results of C101248 demonstrating its pharmacological activity and validation of the NETSseq platform as an effective method to interpret new therapeutic targets for Alzheimer’s disease  He also elaborated on how the combination of the NETSseq platform and C101248 will help in the identification and development of…
March 20, 2023

Read more